Compare Inovio Pharmaceuticals Inc (INO) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs NIO Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while NIO Inc. trades at $4.81 (market cap $12.55B). The key difference: NIO Inc. is far larger — about 140.6× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| INO | NIO | |
|---|---|---|
Market Cap | $89.27M | $12.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $7.89 |
52-Week Low | $1.05 | $4.44 |
Enterprise Value | $60.28M | $11.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
NIO trades at $4.79, down 1.84% with bearish technical signals despite strong delivery growth. The company shows improving fundamentals with revenue reaching $87.49B in 2025 and narrowing losses, though it remains unprofitable with negative cash flow. Analyst sentiment is mixed with 54% buy ratings but technical indicators show selling pressure. Recent vehicle deliveries surged 62.9% year-over-year in June 2026, providing optimism for margin improvement.
NIO presents a high-risk opportunity with significant growth potential but persistent profitability challenges. The stock offers exposure to China's EV market expansion but faces execution risks and competitive pressures. While delivery momentum is strong, investors must weigh the company's cash burn against its market position and Goldman Sachs' recent upgrade to buy with $7 target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
